Adlai Nortye Group (ANL) vs Ginkgo Bioworks (DNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Adlai Nortye Group (ANL) has outperformed Ginkgo Bioworks (DNA) over the past year, gaining 796.5% versus a loss of 22.6%. Adlai Nortye Group is the larger company by market cap ($998.8 million vs $763.6 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANL | DNA |
|---|---|---|
| Share price | $15.51 | $11.34 |
| Market cap | $998.81M | $763.64M |
| 1-day change | +10.39% | -1.13% |
| YTD return | +992.25% | +38.03% |
| 1-year return | +796.53% | -22.60% |
| 5-year return | — | -97.59% |
| EPS (TTM) | $-0.66 | $-5.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.25 | $18.22 |
| 52-week low | $0.879 | $5.37 |
| Distance from 52-week high | -10.09% | -37.76% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +90.20% | -38.27% |
| Average volume | 175.26K | 1.77M |
| Shares outstanding | 58.73M | 55.38M |
| Employees | 109 | 485 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANL has outperformed DNA by 819.1 percentage points over the past year.
About Adlai Nortye Group
ANL stock →Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.
Healthcare · Biotechnology · 109 employees
About Ginkgo Bioworks
DNA stock →Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.
Healthcare · Biotechnology · 485 employees
ANL vs DNA FAQ
Which is bigger, Adlai Nortye Group or Ginkgo Bioworks?
Adlai Nortye Group (ANL) is larger, with a market capitalization of $998.81M compared with $763.64M for Ginkgo Bioworks (DNA).
Which stock has performed better over the past year, ANL or DNA?
ANL returned +796.53% over the past 12 months, compared with -22.60% for DNA (price return, excluding dividends). Past performance does not predict future results.
Are Adlai Nortye Group and Ginkgo Bioworks in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.